Hallmarks of NLRP3 inflammasome activation are observed in organotypic hippocampal slice culture

Christopher Hoyle,1,2 Elena Redondo-Castro,1,2 James Cook,1,2 Te-Chen Tzeng,3 Stuart M. Allan,1,2 David Brough1,2* and Eloise Lemarchand1,2

1Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK, 2The Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, UK and 3Immunology and Inflammation, Bristol-Myers Squibb (Celgene Corporation), Cambridge, MA, USA

doi:10.1111/imm.13221
Received 20 March 2020; revised 5 May 2020; accepted 18 May 2020.
*Correspondence: David Brough, Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, AV Hill Building, Oxford Road, Manchester M13 9PT, UK. Email: david.brough@manchester.ac.uk
Senior author: David Brough

Summary
Microglial inflammation driven by the NACHT, LRR and PYD domain-containing protein 3 (NLRP3) inflammasome contributes to brain disease and is a therapeutic target. Most mechanistic studies on NLRP3 activation use two-dimensional pure microglial cell culture systems. Here we studied the activation of the NLRP3 inflammasome in organotypic hippocampal slices, which allowed us to investigate microglial NLRP3 activation in a three-dimensional, complex tissue architecture. Toll-like receptor 2 and 4 activation primed microglial inflammasome responses in hippocampal slices by increasing NLRP3 and interleukin-1β expression. Nigericin-induced NLRP3 inflammasome activation was dynamically visualized in microglia through ASC speck formation. Downstream caspase-1 activation, gasdermin D cleavage, pyroptotic cell death and interleukin-1β release were also detected, and these findings were consistent when using different NLRP3 stimuli such as ATP and imiquimod. NLRP3 inflammasome pathway inhibitors were effective in organotypic hippocampal slices. Hence, we have highlighted organotypic hippocampal slice culture as a valuable ex vivo tool to allow the future study of NLRP3 inflammasomes in a representative tissue section, aiding the discovery of further mechanistic insights and drug development.

Keywords: interleukin-1β; inflammasome; microglia; NLRP3; organotypic hippocampal slice culture.

Introduction
Microglia are highly dynamic macrophage-like cells that play an integral role in brain development and maintain brain tissue homeostasis by surveillance of the local microenvironment.1 However, microglia also have a critical role in brain pathology, contributing to the progression of diseases such as Alzheimer’s disease, Parkinson’s disease and stroke through the generation of a neuroinflammatory response within the brain parenchyma.2 To reveal new therapeutic targets for brain disease, it is important to identify the cellular mechanisms underlying damaging neuroinflammation. Inflammasomes are important innate immune complexes that regulate the activation of the protease caspase-1 and subsequent maturation and release of the pro-inflammatory cytokines interleukin-1β (IL-1β) and IL-18.3 Several inflammasomes have been described, of which the NACHT, LRR and

Abbreviations: 3D, three-dimensional; ASC, apoptosis-associated speck-like protein containing a caspase recruitment domain; ATP, adenosine triphosphate; BSA, bovine serum albumin; ELISA, enzyme-linked immunosorbent assay; FITC, fluorescein isothiocyanate; IB4, isolecitin GS-IB4 AlexaFluorTM 594 conjugate; IL, interleukin; LPS, lipopolysaccharide; NLRP3, NACHT, LRR and PYD domain-containing protein 3; OHSC, organotypic hippocampal slice culture; PBS, phosphate-buffered saline; PBST, phosphate-buffered saline, 0.1% Tween-20; PCR, polymerase chain reaction; PenStrep, penicillin and streptomycin; PI, propidium iodide; SEM, standard error of the mean; TLR, Toll-like receptor; TNF, tumour necrosis factor; WT, wild-type
PYD domain-containing protein 3 (NLRP3) inflammasome is considered important for driving inflammatory responses in the absence of infection. Without an obvious causal role for infection, the inflammation worsening many brain pathologies is probably caused by host-derived damage-associated stimuli. Hence, the NLRP3 inflammasome is often implicated in the pathology of brain diseases.

Canonical NLRP3 inflammasome activation requires two signals. Signal one is a priming stimulus that typically activates Toll-like receptor (TLR4) or TLR2, driving nuclear factor-κB-dependent expression of inflammatory proteins including NLRP3 and pro-IL-1β, as well as post-translational licensing of NLRP3 through de-ubiquitination, phosphorylation and de-sumoylation. Macrophage metabolic reprogramming upon TLR4 activation also regulates the priming response. Following priming, a second pathogen-associated molecular pattern or damage-associated molecular pattern signal activates NLRP3. Examples of the second NLRP3 activating stimulus include the bacterial toxin nigericin, extracellular adenosine triphosphate (ATP), aggregated amyloid-β and silica crystals. A common feature of the secondary stimuli is often potassium ion efflux from the cell, which is established as a trigger for formation of the NLRP3 inflammasome complex. Potassium ion efflux-independent NLRP3 activation can also be induced by the TLR7 agonist imiquimod. Activated NLRP3 interacts with apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), which polymerizes in the cytosol to form an ASC speck. ASC speck formation facilitates the recruitment and activation of the inflammasome effector protein caspase-1, which in turn induces the proteolytic maturation of pro-IL-1β, allowing mature IL-1β release from the cell. Caspase-1 also triggers cleavage of gasdermin D, the N-terminus of which subsequently forms pores leading to pyroptotic cell death, and which may also form a conduit for IL-1β release. Caspase-1 autoprocessing subsequently terminates its enzymatic activity, limiting the inflammatory response.

Several reports describe canonical NLRP3 inflammasome activation in microglial cultures. However, few studies have demonstrated NLRP3 inflammasome formation in the brain parenchyma. Bernardino et al. reported IL-1β release from murine organotypic hippocampal slice cultures in response to lipopolysaccharide (LPS) and ATP stimulation, and the same treatment also induced IL-1β release from acutely isolated murine and rat hippocampal slices. The presence of microglial and extracellular NLRP3 inflammasomes has been demonstrated both in the post-mortem brains of people with Alzheimer’s disease and in APP/PS1 transgenic mice, as well as in the brains of mice undergoing experimental cerebral malaria.

Despite compelling evidence to suggest an important role for microglial NLRP3 inflammasome responses in brain pathology, our understanding of these pathways within the brain parenchyma remains limited. This is, in part, a result of a lack of ex vivo tools to interrogate NLRP3 inflammasome pathways in a complex brain-like environment. Much of our knowledge is derived from in vitro studies using microglial cell lines or primary microglial cultures, which exhibit an altered transcriptomic profile compared with freshly isolated adult microglia, and this is compounded by the absence of other brain cell types. There is a clear need for a tractable, robust microglial model that better reflects the in vivo setting, facilitating a greater understanding of the underlying neuroinflammatory biology. Here, we used organotypic hippocampal slice cultures (OHSCs), in which the three-dimensional (3D) cellular architecture of the hippocampus was maintained, to investigate microglial NLRP3 inflammasome responses. We demonstrate both priming and activation of NLRP3 inflammasome responses in OHSC microglia. ASC speck formation, caspase-1 activation and cleavage of gasdermin D and IL-1β were detected in OHSCs, and inhibitors of the NLRP3 inflammasome pathway showed efficacy in this model. Hence, we have established OHSCs as a valuable ex vivo tool to interrogate microglial NLRP3 inflammasome responses.

Materials and methods

Mice

Experiments were carried out on an in-house colony of wild-type (WT) or ASC-citrine C57BL/6 mice at the University of Manchester. Animals were allowed free access to food and water and maintained under temperature-, humidity- and light-controlled conditions. All animal procedures adhered to the UK Animals (Scientific Procedures) Act (1986).

OHSC preparation

Seven-day-old mouse pups of either sex were killed by cervical dislocation and the brains were collected in phosphate-buffered saline (PBS) containing glucose (5 mg/ml). Hippocampi were dissected, placed on filter paper and 400-μm slices were cut using a Mcllwain tissue chopper (Brinkman Instruments, Runcorn, UK). Hippocampal slices were collected and placed on 0.4-μm Millicell culture inserts (Millipore, Watford, UK), as previously described by Stoppini et al. Three hippocampal slices were placed on each insert. Slices were maintained in a humidified incubator with 5% CO₂ at 37°C with 1 ml of minimal essential medium (Gibco, Waltham, MA) containing 20% horse serum (Sigma, Poole, UK),
supplemented with HEPES (30 mM; ThermoFisher Scientific, Waltham, MA) and insulin (0.1 mg/ml; Gibco), pH 7.2–7.3. Culture medium was changed every 2 days, and slices were used at day 7.

Primary murine adult microglia preparation

Mice aged 8–10 weeks of either sex were deeply anaesthetized with isofluorane and transcardially perfused with ice-cold PBS. Unless otherwise stated, all subsequent steps were performed on ice or at 4°C. Brains (excluding cerebellum) were excised, minced with a disposable scalpel into 1- to 3-mm³ chunks, and digested using a Neural Tissue Dissociation Kit (Miltenyi, Surrey, UK) according to the manufacturer’s instructions. The resulting suspension was homogenized in a Dounce tissue grinder (Sigma) with 20 strokes of a loose-clearance pestle. The resulting single-cell suspension was depleted of myelin by centrifuging in 33% Percoll (GE Healthcare, Amersham, UK) for 10 min at 1000 g (low brake) and aspirating the myelin layer. Cells were then pelleted by diluting 1:4 in Hanks’ balanced salt solution without calcium or magnesium (Gibco) and centrifuging for 10 min at 500 g. Microglia were magnetically labelled with 10 µl anti-CD11b magnetic microbeads (Miltenyi) per brain in MACS buffer [PBS without calcium or magnesium, with 2 mM ethylenediaminetetraacetic acid and 0.5% bovine serum albumin (BSA)] for 15 min at 4°C followed by positive enrichment on LS columns (Miltenyi) according to the manufacturer’s instructions. The resulting microglia suspension was pelleted, counted and spot-plated onto 96-well Cell+ plates (Sarstedt, Nümbrecht, Germany) at a density of 10 000 cells per well. The plates were incubated briefly at 37°C to allow cell attachment, following which the wells were replenished with 100 µl of culture medium [Dulbecco’s modified Eagle’s medium/F12 (Sigma) containing 10% fetal bovine serum (ThermoFisher), 100 U/ml of penicillin and 100 µg/ml streptomycin (PenStrep; ThermoFisher), 2 mM glutamine] supplemented with IL-34 (20 ng/ml; R&D Systems, Abingdon, UK) and transforming growth factor-β1 (50 ng/ml; Miltenyi)]. Cells were used at day 7.

Primary murine mixed glial culture preparation

Murine mixed glial cells were prepared from the brains of 2- to 4-day-old mice of either sex that were killed by cervical dislocation. The brains were isolated and the cerebral hemispheres were dissected and the meninges were removed. The remaining tissue was homogenized in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum and PenStrep via repeated trituration. The resulting homogenate was centrifuged at 500 g for 10 min and the pellet was resuspended in fresh culture medium before being incubated in a flask at 37°C, 90% humidity and 5% CO₂. After 5 days, the cells were washed and fresh medium was placed on the cells. The medium was replaced every 2 days. On day 12, the cells were seeded at 2 × 10⁵ cells/ml in 24-well plates and incubated for a further 2 days before use.

Priming assays

The OHSCs, adult microglia and murine mixed glia were primed with vehicle (PBS), LPS (1 µg/ml; Sigma) or Pam3CSK4 (100 ng/ml; 3 hr; InvivoGen, Toulouse, France) in culture medium containing serum. Supernatants were collected, and OHSCs were prepared for quantitative polymerase chain reaction (PCR), immunofluorescence staining or Western blotting.

OHSC inflammasome activation assays

The OHSCs were primed with LPS (1 µg/ml, 3 hr) in culture medium containing serum. The medium was then replaced with serum-free culture medium, and in some experiments, drugs were spiked into this medium for 15–60 min. These drugs were MCC950 (10 µM; Sigma), ac-YVAD-cmk (100 µM; VWR International, Luttworth, UK), VX-765 (100 µM; Selleckchem), ZVAD-fmk (50 µM; Merck, Watford, UK) and NBC19 (25 µM). After drug pre-treatment, the following soluble NLRP3 inflammasome stimuli were spiked into the culture medium: nigericin (10 µM, 0–90 min; Sigma), ATP (5 mM, 90 min; Sigma) and imiquimod (75 µM, 2 hr; InvivoGen). To activate the NLRP3 inflammasome with insoluble stimuli, silica (3 µl, 3 mg/ml, 24 hr; US Silica, Katy, TX) was pipetted directly on top of each hippocampal slice on each insert. Following inflammasome activation, culture medium was collected and analysed for cytokine content by enzyme-linked immunosorbent assay (ELISA), or for content of specific proteins by Western blotting. Hippocampal slices were prepared for either Western blotting or immunostaining.

Adult microglia and mixed glia inflammasome activation assays

Cells were primed with LPS (1 µg/ml, 3 hr) in culture medium containing serum. The medium was then replaced with serum-free culture medium in the presence or absence of MCC950 (10 µM, 15 min). After drug pre-treatment, NLRP3 inflammasome activation was induced by in the addition of nigericin (10 µM, 60 min), ATP (5 mM, 60 min) or imiquimod (75 µM, 2 hr). Silica (0.3 mg/ml) was added simultaneously with MCC950 for 24 hr (adult microglia) or 4 hr (mixed glia).

Western blotting

The OHSCs, adult microglia and mixed glia were lysed with lysis buffer (50 mM Tris–HCl, 150 mM NaCl, Triton X% volume/volume, pH 7.3) containing protease.
inhibitor cocktail (Calbiochem, Watford, UK). The OHSCs were additionally lysed using repeated trituration and brief water bath sonication. Lysates were then centrifuged for 10 min at 12,000 g at 4°C and analysed for pro-IL-1β, mature IL-1β, NLRP3, pro-caspase-1, caspase-1 p10 and gasdermin D. Equal amounts of protein were loaded from lysates, whereas equal volumes of supernatants were loaded. Samples were run on sodium dodecyl sul[hydrate–polyacrylamide gels and transferred at 25 V onto nitrocellulose or PVDF membranes using a Trans-Blot® Turbo Transfer™ System (Bio-Rad, Watford, UK). Membranes were blocked in either 5% weight/volume milk or 2.5% BSA (Sigma) in PBS, 0.1% Tween-20 (PBST) for 1 h at room temperature. The membranes were then washed with PBST and incubated at 4°C overnight with goat anti-mouse IL-1β (250 ng/ml; R&D Systems, Cat# AF-401-NA), mouse anti-mouse NLRP3 (1 µg/ml; Adipogen, Cat# AG-20B-0014-C100), rabbit anti-mouse caspase-1 (1.87 µg/ml; Abcam, Waltham, MA, Cat# ab179515) or rabbit anti-mouse gasdermin D (0.62 µg/ml; Abcam, Cat# ab209845) primary antibodies in 0.1% (IL-1β), 1% (NLRP3) or 2.5% caspase-1, gasdermin D) BSA in PBST. Membranes were washed and incubated with rabbit anti-goat (500 ng/ml, 5% milk in PBST; Dako, Stockport, UK, Cat# P044901-2), rabbit anti-mouse (1.3 µg/ml, 5% milk in PBST; Dako, Cat# P026002-2) or goat anti-rabbit IgG (250 ng/ml, 2.5% BSA in PBST; Dako, Cat# P044801-2) at room temperature for 1 h. Proteins were then visualized with Amersham ECL Western Blotting Detection Reagent (GE Life Sciences, Amersham, UK) and Genesys software (Syngene). β-Actin (Sigma, Cat# A3854) was used as a loading control.

Immunostaining

The OHSCs were washed once with cold PBS and fixed in 4% paraformaldehyde (1 hr) at 4°C. OHSCs were washed twice more in cold PBS and then incubated with goat anti-mouse IL-1β (2 µg/ml; R&D Systems, Cat# AF-401-NA), rabbit anti-mouse Iba-1 (1.294 µg/ml; Abcam, Cat# ab178846) or rabbit anti-mouse ASC (202 ng/ml; Cell Signaling Technology, Waltham, MA, Cat# 67824) primary antibodies overnight at 4°C. OHSCs were washed and incubated with AlexaFluor™ 488 donkey anti-rabbit IgG (2 µg/ml; Invitrogen, Waltham, MA, Cat# A-21206), AlexaFluor 594 donkey anti-rabbit IgG (2 µg/ml; Invitrogen, Cat# A-21207) or AlexaFluor 647 donkey anti-rabbit IgG (4 µg/ml; Invitrogen, Cat# A32795) secondary antibodies for 2 hr at room temperature. For IL-1β immunostaining, biotin amplification was performed using biotinylated anti-goat IgG antibody (7.5 µg/ml, 2 hr at room temperature; Vector Laboratories, Peterborough, UK, Cat# BA-9500), before washing and subsequent incubation in streptavidin AlexaFluor 546 conjugate (5 µg/ml; Invitrogen, Cat# S11225). All antibody incubations were performed using PBS, 0.3% Triton X-100. Wash steps were performed using PBST unless stated otherwise. OHSCs were washed and then incubated in DAPI (1 µg/ml, 15 min; Sigma, Cat# D9542) at room temperature before final washing and mounting using ProLong gold antifade mountant (ThermoFisher) before imaging using wide-field or confocal microscopy.

Reverse transcription quantitative PCR

Total RNA was extracted from samples with TRIzol Reagent (ThermoFisher) according to the manufacturer's instructions. RNA (1 µg) was converted to cDNA using Superscript III Reverse Transcriptase (ThermoFisher). Quantitative PCR was performed using Power SYBR® Green PCR Master Mix (ThermoFisher) in a 384-well format using a 7900HT Fast Real-Time PCR System (Applied Biosystems, Waltham, MA), and 3 µl of 1:20-diluted cDNA was loaded with 200 nmol/l of primers in triplicate. Data were normalized to the expression of the housekeeping gene Hmbs or Actb. Expression levels of genes of interest were computed as follows: relative mRNA expression = $E^\Delta C_t$/($E^\Delta C_t$ of housekeeping gene), where $C_t$ is the threshold cycle value and $E$ is efficiency. Primers used were: NLRP3 forward, GCCCAAGGAAGAAGAAC, NLRP3 reverse, TCCGGTTGGTCTTAGA CTT; Pycard forward, TGCTTAGACATGCGCTTACA, Pycard reverse, ACTCTGAGCAGGACACTG; Caspase-1 forward, CATTTGTAATGAAGACTGCTACCTG, Caspase-1 reverse, GATGTCTCTTATGAACTCTCTGT; GSDMD forward, TGCAGATCAGGAGGTCCAC, GSDMD reverse, GCCCTCACCCTTCAAGCATA; IL-1β forward, AACCCTG CTGGGTGTGACGTTC, IL-1β reverse, CAGCGACCAGGCTTTTTTGTTGT; IL-18 forward, GAGTGGGTCTCCTTTTAAGGCA; tumour necrosis factor (TNF) forward, CCCTCACACT CAGATCATCTCT, TNF reverse, GCTAGACGCGCGGTACAG; IL-1α forward, CTTCGAGATCTCCATGTTGTC, IL-1α reverse, AGAAAATGGTGGGTCTGTACTCA; IL-6 forward, CTCTGGGGAAATCGTGGAAAT, IL-6 reverse, CCGTGGGAAATCGTGGAAAT.

ELISA

The levels of IL-1β in the supernatant were analysed by ELISA (DuoSet, R&D Systems) according to the manufacturer’s instructions.

Cell death assays

Cell death in the hippocampal slices was assessed by adding propidium iodide (25 µg/ml; Sigma) to the culture medium for the final 30 min of inflammasome activation. Cell death in microglial cultures was assessed by measuring lactate dehydrogenase release into the supernatant.
using a CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega, Southampton, UK) according to the manufacturer’s instructions. Supernatants containing silica were centrifuged at 12 000 g (10 min) at 4°C before analysis to remove silica.

**Snapshot wide-field microscopy**

Images were collected on a Zeiss Axioimager.M2 upright microscope using a 5× or 20× Plan Apochromat objective and captured using a Coolsnap HQ2 camera (Photometrics, Birmingham, UK) through MicroManager software (v1.4.23). Specific band-pass filter sets for DAPI, fluorescein isothiocyanate (FITC), Cy3 and Texas Red were used to prevent bleed-through from one channel to the next.

**Confocal microscopy**

Images were collected on a Leica TCS SP8 AOB S upright confocal microscope through LAS X (v3.5.2.18963) using a 63X/1.40 HCPL APO objective and 1× confocal zoom. The confocal settings were as follows: pinhole 1 airy unit, scan speed 400 Hz bidirectional, format 1024×1024. The white-light laser was used with FITC 488 nm, Cy3 555 nm, Texas Red 594 nm and Cy5 647 nm laser lines. Images were collected using hybrid and photon-multiplying tube detectors with the following detection mirror settings: DAPI 410–520 nm, Cy3 565–636 nm and Cy5 657–744 nm for IL-1β/Iba1 images; and DAPI 410–478 nm, FITC 498–584 nm and Texas Red 604–749 nm for ASC/Iba1 images. Images were collected sequentially to eliminate crosstalk between channels. For live imaging, OHSCs were LPS-primed (1 µg/ml, 3 hr) and then medium was replaced with phenol-red-free, serum-free culture medium containing Hoechst (2 µg/ml; ThermoFisher) and isoelectric GS-IB4-AlexaFluor 594 conjugate (from Griffonia simplicifolia; IB4; 5 µg/ml; ThermoFisher) and incubated for 2 hr at 37°C. OHSCs were subsequently covered with 1.5 ml phenol-red-free, serum-free medium to allow lens immersion, and then nigericin (10 µM) was spiked into the culture medium underneath the insert. The OHSCs were then placed into a confocal microscope chamber heated to 37°C and imaged for 60–90 min.

**Image processing analysis**

Analysis was performed using FIJI (ImageJ, NIH, Bethesda, MD) on images acquired from the same region of three separate OHSCs (from the same insert) per treatment, and these values were averaged for each biological repeat. IL-1β and Iba1 colocalization was quantified on 63× z-stacks acquired on a confocal microscope. The number of IL-1β-positive cells in each stack was counted manually. Each of these IL-1β-positive cells was simultaneously assessed for Iba1 signal. ASC speck formation was quantified on 20× wide-field microscope images by subtracting background (50-pixel rolling ball radius), autothresholding using the triangle method and analysing particles with the following thresholds: size 1–10 µm², circularity 0.9–1.0. In cases of low or no ASC speck formation, manual thresholding was performed to ensure accurate quantification of ASC speck number. To quantify propidium iodide (PI) uptake, images were acquired on a wide-field microscope using a 5× objective, background was subtracted (5.0-pixel rolling ball radius) and images were automatically thresholded using the default method. In cases of low or no detectable cell death, images were manually thresholded to ensure that all PI-positive cells were included. The total area of PI-positive signal was measured in the whole field of view, and was then normalized to the total area of DAPI signal. ASC speck spatial localization was determined using 63× z-stacks acquired on a confocal microscope. The total number of ASC specks through the z-stack was counted manually, and each speck present in an Iba1-positive cell was classed as perinuclear (≤2 µm from the nucleus) or cytosolic (> 2 µm from the nucleus). ASC specks that were not in an Iba1-positive cell were labelled as unclassified. All 3D reconstructions from z-stacks were generated using IMARIS software (v9.3.1; Bitplane, Zurich, Switzerland).

**Statistical analysis**

Data are presented as the mean ± standard error of the mean (SEM) overlaid with individual data points. Transformations or corrections were applied as necessary to obtain equal variance between groups before analysis. Data were analysed using two-tailed unpaired t-tests or repeated-measures one-way analysis of variance with Dunnett’s post-hoc test using GraphPad PRISM (v7; GraphPad, San Diego, CA). Statistical signficance was accepted at *P < 0.05, **P < 0.01 and ***P < 0.001.

**Results**

NLRP3 inflammasome priming by TLR stimuli in OHSCs

A schematic demonstrating OHSC preparation and the treatment protocol is shown in Fig. 1(a). Canonical NLRP3 inflammasome-dependent IL-1β processing and release has a well-defined two-step activation mechanism. Priming is achieved in vitro through the activation of TLR4 or TLR2, both of which are expressed by microglia in the brain.38,39 Consistent with this, treatment of WT OHSCs with the TLR4 agonist LPS, or the TLR2 agonist Pam3CSK4, induced the up-regulation of Il1b, Nlrp3, Tnf, Il6 and Il1a gene mRNA levels (Fig. 1b). Pycard (ASC),

© 2020 The Authors. Immunology published by John Wiley & Sons Ltd, Immunology, 161, 39–52
Casp1, Gsdmd and Il18 were not significantly up-regulated by either stimulus and were constitutively expressed (see Supplementary material, Fig. S1). Using immunofluorescence staining, pro-IL-1β protein production was observed throughout the OHSCs in response to LPS and Pam3CSK4 priming, and was expressed almost exclusively by Iba1-positive microglia (Fig. 1ci, cii; and see Supplementary material, Video S1) 40. Up-regulation of pro-IL-1β and NLRP3 protein expression was confirmed by Western blotting of OHSC lysates, as well as lysates of cultured adult murine microglia and primary murine mixed glia, which were run in parallel as a control (Fig. 1d).

ASC speck formation can be visualized using ASC–citrine OHSCs

Having confirmed that OHSCs had a normal NLRP3 inflammasome priming response, we next sought to investigate whether canonical NLRP3 inflammasome activation could also be elicited in OHSCs. To do this, we used a transgenic mouse in which fluorescent ASC–citrine fusion protein is expressed.36 The response of ASC–citrine OHSCs to priming stimuli was similar to WT OHSCs (Fig. 2a,b). Subsequently, ASC–citrine OHSCs were primed with LPS and incubated in isolecitin GS-IB4 Alexafluor 594 conjugate (IB4), which primarily stains microglia in the central nervous system, before treatment with the NLRP3 activator Nigericin.41 ASC speck formation was assessed using time-lapse confocal microscopy, and image acquisition was begun 10–20 min after Nigericin addition (see Supplementary material, Video S2). Images at 30-min time-points after starting image acquisition are shown, as well as an enlarged region of the image at 2-min intervals (Fig. 2a). ASC specks formed throughout the time-course of Nigericin treatment, and these ASC specks were predominantly in IB4-positive microglia (Fig. 2a). In some cases, ASC specks had already formed before acquisition of the first image. The ASC specks formed in response to Nigericin remained cell-associated for the duration of the recording in the absence of a caspase-1 inhibitor, suggesting that they were not immediately released into the extracellular environment as a result of cell death (Fig. 2a). These findings were validated by using wide-field microscopy to assess ASC speck formation in ASC–citrine OHSCs that had been fixed at 30-min time-points after Nigericin treatment. Similar to the live imaging, ASC speck formation was detected in ASC–citrine OHSCs after 30 min of Nigericin treatment, with the number of ASC specks increasing up to 60 min following treatment (Fig. 2b). It is important to note that large aggregates of ASC–citrine were observed in all ASC–citrine OHSCs, even in the absence of treatment, possibly resulting from the overexpression of ASC, which has a high propensity to aggregate because of its prion-like properties (Fig. 2b; and see Supplementary material, Fig. S2C).36,42 These aggregates were much larger than ASC specks and were excluded from ASC speck quantification.

The characteristics of ASC speck formation in OHSCs, including the cell types in which they formed and their subcellular localization, were further investigated. Representative 3D projections and y-planes of ASC speck-expressing OHSCs are shown (Fig. 2ci). 3D reconstructions illustrate the peri-nuclear and peripheral subcellular locations of the ASC speck. Approximately 80% of ASC specks formed in Iba1-positive microglia, with 50% of total ASC specks observed in the perinuclear region of Iba1-positive microglia and 30% present in the peripheral cytosol (Fig. 2cii). The remaining ASC specks could not be classified. They did not appear to be present in Iba1-positive microglia but could be extracellular or in non-labelled cells (Fig. 2cii).43

Validation of ASC speck formation in WT OSHCs

NLRP3-dependent ASC speck formation was next investigated in WT OHSCs expressing only endogenous ASC. WT OHSCs were treated with LPS followed by Nigericin and were then fixed and probed for ASC using immunofluorescence staining as described above. Diffuse ASC staining was observed in LPS-primed OHSCs, whereas ASC specks could be detected in LPS-primed OHSCs treated with Nigericin (Fig. 3). Interleukin-1β was also detected in the culture medium, indicating that these ASC specks were active (Fig. 3). The NLRP3 inflammasome inhibitor MCC95044 blocked both ASC speck formation and IL-1β release, confirming that these processes were NLRP3 dependent (Fig. 3). Inflammasome activation also induces

---

**Figure 1.** NACHT, LRR and PYD domain-containing protein 3 (NLRP3) inflammasome priming by Toll-like receptor (TLR) stimuli in organotypic hippocampal slice cultures (OHSCs). (a) Schematic of OHSC preparation and treatment protocol. (b–d) Wild-type (WT) OHSCs were primed with vehicle (phosphate-buffered saline; PBS), lipopolysaccharide (LPS) (1 µg/ml) or Pam3CSK4 n in culture medium containing serum. OHSCs were then processed for downstream RNA and protein analysis. (b) The expression of various inflammatory gene mRNA levels was assessed by quantitative PCR (n = 4). (c) OHSCs were stained for nuclei (DAPI, blue), interleukin-1β (IL-1β) (cyan) and Iba1 (red) (n = 3). Images were acquired using wide-field (5×) and confocal (63×) microscopy. Enlarged merge images show regions denoted by the white box. Scale bars are 200 µm (wide-field) or 25 µm (confocal). (See also Supplementary material, Video S1). (cii) IL-1β-positive cells were quantified and assessed for co-expression of Iba1 signal. (d) WT OHSCs, adult microglia and mixed glia lysates were assessed for pro-IL-1β and NLRP3 content by Western blotting (n = 3). Data are presented as mean ± SEM. Data were analysed using repeated-measures one-way analysis of variance with Dunnett’s post-hoc test. ns, Not significant; *P < 0.05; **P < 0.01; ***P < 0.001.
NLRP3 inflammasome activation in OHSCs

(a) OHSC preparation

(b) Relative expression

Relative expression

PBS LPS Pam3CSK4 PBS LPS Pam3CSK4 PBS LPS Pam3CSK4 PBS LPS Pam3CSK4

(c) (i) Widefield

DAPI/IL-1β DAPI IL-1β Iba1 DAPI/IL-1β/Iba1 Enlarged merge

(ii) Pro-IL-1β NLRP3 β-actin

PBS LPS Pam PBS LPS Pam PBS LPS Pam

© 2020 The Authors. Immunology published by John Wiley & Sons Ltd, Immunology, 161, 39–52
C. Hoyle et al.

(a) 

![Image](image_url)

(b) 

![Image](image_url)

(c) (i) 

![Image](image_url)

(ii) 

![Image](image_url)

© 2020 The Authors. Immunology published by John Wiley & Sons Ltd, Immunology, 161, 39–52
pyroptotic cell death, and to measure this, OHSCs were incubated with PI, added for the final 30 min of nigericin treatment. Nigericin treatment induced cell death throughout the OHSCs, and this was reduced by MCC950, suggesting that there was inflammasome-dependent pyroptotic death in response to nigericin (Fig. 3).

Different canonical NLRP3 stimuli induce inflammasome activation

To further characterize canonical NLRP3 inflammasome responses, LPS-primed WT OHSCs were treated with nigericin for 90 min, and Western blotting was used to measure markers of inflammasome activation. Active caspase-1 p10, cleaved gasdermin D and mature IL-1β were detected in the OHSCs as early as 30 min after nigericin treatment, with less mature IL-1β and caspase-1 p10 detected in the OHSCs at the 60- and 90-min time-points (Fig. 4a). Western blotting and ELISA of the culture medium confirmed that IL-1β and caspase-1 were being released from the OHSCs after their cleavage (Fig. 4a). MCC950 blocked caspase-1 and IL-1β activation and release, as well as gasdermin D cleavage (Fig. 4a). Caspase-1 inhibition with Ac-YVAD-cmk or VX-765,55 pan-caspase inhibition with ZVAD-fmk, or NLRP3 inflammasome inhibition using MCC950 or the recently described NBC1946 all inhibited caspase-1 activation, gasdermin D cleavage, and IL-1β processing and release from WT OHSCs after 30 min of nigericin treatment (Fig. 4b).

A range of stimuli has been described to activate the canonical NLRP3 pathway, including extracellular ATP, imiquimod and particulates such as silica crystals.13–15,17 Hence, additional NLRP3 agonists were tested to determine their potential to activate the NLRP3 inflammasome in OHSCs. LPS-primed WT OHSCs were treated with ATP, imiquimod or silica, and these induced caspase-1 activation, gasdermin D cleavage and release of IL-1β, all of which were prevented by MCC950 treatment (Fig. 4c–e; see Supplementary material, Fig. S3A–C). Mature IL-1β and caspase-1 p10 were also detected in the culture medium by Western blotting, although caspase-1 p10 was often present at low levels (Fig. S3A–C). ASC speck formation and IL-1β release in response to ATP and imiquimod were further confirmed in ASC–citrine OHSCs (Fig. S3D,E). We then compared the NLRP3 inflammasome response of OHSCs with other microglial systems. Interleukin-1β release and cell death in response to nigericin, ATP, imiquimod and silica were consistent in both primary adult microglia and primary mixed glial cultures, and IL-1β release was inhibited by MCC950 in all cases (Fig. S4A–H).

Discussion

Microglial NLRP3 inflammasome responses play an important role in neuroinflammation associated with brain pathology.2,2 However, a gap exists between in vivo observations of microglial neuroinflammatory mechanisms and respective in vitro models, which currently focus mainly on pure microglial monolayer cultures.34,47 This is reflected by recent identification of heterogeneous microglial populations within the central nervous system by single-cell RNA-Seq, highlighting the need for more complex, integrated microglial models to better reflect their physiology.18–50 To address this, we investigated microglial NLRP3 inflammasome responses in a complex 3D ex vivo brain-like environment. We demonstrated that OHSCs exhibit robust microglial NLRP3 inflammasome priming and activation, indicating that OHSCs can aid the generation of important new insights into microglial neuroinflammatory mechanisms.

The OHSC model of NLRP3 inflammasome activation in microglia begins to bridge the gap between mechanistic insights into NLRP3 regulation derived from in vitro studies and in vivo observations that demonstrate NLRP3 inflammasome relevance in the brain.31–33,51 Our findings
Figure 3. Validation of ASC speck formation in wild-type organotypic hippocampal slice cultures (WT OHSCs). WT OHSCs were primed with lipopolysaccharide (LPS) (1 µg/ml, 3 hr) before treatment with MCC950 (MCC; 10 µM, 15 min) where appropriate and addition of nigericin (10 µM, 0–90 min; n = 4). Propidium iodide (PI; red, 25 µg/ml) was added for the final 30 min of nigericin treatment. OHSCs were probed for nuclei (DAPI, blue) and ASC (green) by immunofluorescence staining. Images were acquired using wide-field microscopy at 20× (ASC) and 5× (PI) magnification. Scale bars are 200 µm. The ASC speck number was quantified. The area of PI-positive staining is expressed as a % of total area of DAPI staining. Supernatant was also assessed for IL-1β content by ELISA. Data are presented as mean ± SEM. Data were analysed using repeated-measures one-way analysis of variance with Dunnett’s post-hoc test. ns, Not significant; *P < 0.05; **P < 0.01; ***P < 0.001.

Figure 4. Different canonical NACHT, LRR and PYD domain-containing protein 3 (NLRP3) stimuli induce inflammasome activation. (a) Wild-type organotypic hippocampal slice cultures (WT OHSCs) were untreated or primed with lipopolysaccharide (LPS) (1 µg/ml, 3 hr), before treatment with MCC950 (10 µM, 15 min) before the addition of nigericin (10 µM, 0–90 min; n = 4). OHSC lysates and supernatants were probed by Western blotting for markers of inflammasome activation. Supernatants were also assessed for interleukin-1β (IL-1β) content by ELISA. (b) WT OHSCs were primed with LPS (1 µg/ml, 3 hr), before treatment with ac-YVAD-cmk (100 µM, 15 min), VX-765 (10 µM, 15 min), ZVAD-fmk (50 µM, 15 min), MCC950 (10 µM, 15 min) or NBC19 (25 µM, 15 min), before the addition of nigericin (10 µM, 30 min; n = 4). OHSC lysates were probed for markers of inflammasome activation by Western blotting. Interleukin-1β release into the supernatant was measured by ELISA. (c–e) WT OHSCs were treated with LPS (1 µg/ml, 3 hr), before treatment with MCC950 (10 µM, 15 min), before the addition of (c) ATP (5 mM, 90 min; n = 4), (d) imiquimod (75 µM, 2 hr; n = 4) or (e) silica (3 µl, 3 mg/ml, 24 hr; n = 4). Silica was pipetted directly on top of each OHSC. Supernatant was assessed for IL-1β content by ELISA. Data are presented as mean ± SEM. Data were analysed using repeated-measures one-way analysis of variance with Dunnett’s post-hoc test. ns, Not significant; *P < 0.05; **P < 0.01; ***P < 0.001.
NLRP3 inflammasome activation in OHSCs
are supported by reports of IL-1β release from murine OHSCs and acutely isolated rat hippocampal slices in response to LPS and ATP treatment.29,30,52 Spontaneous epileptiform activity has also been suggested to increase NLRP3 and inflammatory cytokine expression in rat OHSCs.53 Hence, by using OHSCs, we can begin to disentangle pathophysiological mechanisms of neuroinflammation in an environment more representative of the brain parenchyma.

Although there are several limitations to the use of OHSCs, they were selected primarily because they maintain a 3D cellular architecture, preserving the interactions and connectivity between microglia, astrocytes and neurons. These cell–cell interactions are critical for microglial function, as astrocytes secrete various factors such as transforming growth factor-β, colony-stimulating factor-1 and cholesterol that promote microglial survival.54 Furthermore, the OHSC vasculature is still present during culture, despite the absence of blood flow.55,56 Other studies have used acutely prepared hippocampal slices from adult rodents to investigate microglial function.30,57 Although these models confer many benefits for studying microglia ex vivo, there are major differences with OHSCs. For example, microglia from acute brain slices develop an amoeboid morphology in response to neuronal injury during the 24-hr period after sectioning.58 Any resulting investigations would therefore be performed in an already inflammatory environment. However, in OHSCs, the inflammatory response induced by the initial injury subsides over the course of the culture, meaning that by the time of inflammatory perturbation, the microglia appear more ramified and the production of inflammatory cytokines is reduced.59 Our data support this, as the expression of various cytokines was negligible after 7 days of culture. The study of OHSCs repopulated with adult microglia has also been characterized.60 Various methods have employed human induced pluripotent stem cells, or microglia acquired from post-mortem tissue, to study the role of human microglia.61,62 However, in isolation, these models lack the complex interplay between microglia, astrocytes and neurons. 3D cerebral organoids can be developed from human induced pluripotent stem cells to investigate human microglia in a more brain-like environment, but they lack vasculature and typically exhibit high variability among individual organoids, although recent progress has been made in this regard.63–65

We have demonstrated various fundamental applications of OHSCs with regard to studying microglial inflammatory responses, presenting opportunities to further interrogate neuroinflammation. We highlight OHSCs as a model in which to investigate mechanisms of NLRP3 inflammasome priming in microglia. For example, the precise mechanisms of microglial priming in acute brain injuries such as stroke, including identification of the endogenous damage-associated stimuli, are unclear. Furthermore, we show that live imaging can be performed on OHSCs, offering a tractable system for easier investigation and hypothesis testing than in vivo imaging, but one that maintains physiological relevance compared with purely in vitro studies. Implications of NLRP3 inflammasome activation could be studied in OHSCs, such as characterizing the longer-term fate of ASC specks following pyroptotic cell death. Furthermore, because of the absence of blood and lymphatic flow, intrinsic properties of the OHSCs can be isolated. Hence, it can be determined whether ASC speck clearance can be mediated by the cells within the tissue itself, such as by phagocytosis, or whether cellular infiltration may be a requirement for the resolution of an inflammatory response. Exogenous addition of peripheral cells to OHSCs has previously been performed, and this would allow examination of the effects of infiltrating peripheral cells.66 Heterogeneity of inflammatory responses could also be investigated in slice cultures prepared from different brain regions, as well as between male and female mice.

We have demonstrated that OHSCs are a tractable model to interrogate microglial NLRP3 inflammasome responses. Our data indicate that, in OHSCs, microglia are NLRP3 inflammasome-competent cells that exhibit robust canonical NLRP3 inflammasome priming and activation. This model provides a platform from which to address a wide range of critical questions in the field. Incorporating OHSCs into the existing pool of established cell and tissue models for studying inflammasomes would help to advance the study of brain inflammasome responses, further enhancing our understanding of the role of inflammasomes and microglia in brain inflammation and disease.

Author contributions

Conceptualization, E.L., D.B. and S.M.A; methodology, C.H., E.L. and D.B.; investigation, C.H., E.L., E.R-C. and J.C.; resources, T-C.T.; writing – original draft, C.H.; writing – review and editing, C.H., E.L., D.B. and S.M.A; supervision, D.B. and S.M.A; funding acquisition, D.B. and S.M.A.

Acknowledgements

The ASC-citrine mice were a kind gift from Douglas Golenbock (University of Massachusetts Medical School).

Funding information

This work was funded by the MRC (Grant No. MR/N003586/1 to D.B. and S.M.A.) and was also funded by an MRC PhD studentship to C.H. (Grant No. MR/N013751/1). The Bioimaging Facility microscopes used in this study were purchased with grants from BBSRC, Wellcome and the University of Manchester Strategic Fund.
Disclosures
The authors declare no conflicts of interest.

Data availability statement
The data set that supports the findings of this study are available from the corresponding author upon reasonable request.

References
1. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillance of brain parenchyma in vivo. Science (80-). 2005;308:1314–8.
2. Wolf SA, Boddeke H, Kettenmann H. Microglia in physiology and disease. Annu Rev Physiol 2017; 79:619–43.
3. Schröder K, Tschopp J. The inflammasomes. Cell 2010; 140:821–32.
4. Rock KL, Lutz E, Outeiroro F, Kono H. The sterile inflammatory response. Annu Rev Immunol 2011; 29:321–52.
5. Heneka MT, McManus RM, Lutz E. Inflammasome signalling in brain function and neurodegenerative disease. Nat Rev Neurosci 2018; 19:610–20.
6. Lopez-Castrojon G, Lukshe NM, Compan V, High S, Whitelock RC, Flinth S et al. Deubiquitinites regulate the activity of caspase-1 and interleukin-1β secretion via assembly of the inflammasome. J Biol Chem 2013; 288:2771–83.
7. Song N, Liu ZS, Xue W, Bai ZF, Wang QY, Dai J et al. NLRP3 phosphorylation is an essential priming event for inflammasome activation. Mol Cell 2017; 68:185–197.e6.
8. Bauereinr GF, Hovarth G, Stutz A, Altenri ES, MacDonald K, Sprent D et al. Cutting edge: NF-κB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol 2009; 183:787–91.
9. Barry R, John SW, Liscardi G, Tener T, Jiao I, Chen CH et al. SUMO-mediated regulation of NLRP3 modulates inflammasome activity. Nat Commun 2011; 2:9001.
10. Hoyle C, Rivers-Auty J, Lemarchand E, Vranic S, Wang E, Buggio M et al. Geminin D causes pyroptosis by forming membrane pores. Nature 2016; 535:153–8.
11. He WT, Wan H, Lu L, Chen P, Wang X, Huang Z et al. Geminin D is an executor of pyroptosis and required for interleukin-1β secretion. Cell Res 2015; 25:1285–98.
12. Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 2015; 526:660–5.
13. Boucher DJ, Monteforte M, Cell BC, Chou KW, Ross CM, Too IL et al. Caspase-1 self-cleavage is an intrinsic mechanism to terminate inflammasome activity. J Exp Med 2015; 213:827–40.
14. Redondo-Castro E, Faust D, Fox S, Baldwin AG, Osborne S, Haley MJ et al. Development of a characterised tool kit for the interrogation of NLRP3 inflammasome-dependent responses. Sci Rep 2018; 8:5606.
15. Schellach H, Schlatter A, Golenbock DT, Lutz E, Martinez-Martinez P, Heneka MT. Activation of the NLRP3 inflammasome in microglia: the role of ceramide. J Neurinchem 2017; 143:534–50.
16. Broudh D, Le Feuvre RA, Iwakura Y, Rothsfield NJ. Purinergic (P2X7) receptor activation of microglia induces cell death via an interleukin-1-independent mechanism. Mol Cell Neurosci 2002; 19:272–80.
17. Bernardino L, Balosso S, Ravizza T, Marchi N, Guo G, Randle JC et al. Inflammatory events in hippocampal slice cultures prime neuronal susceptibility to excitotoxic injury: a crucial role of P2X7 receptor-mediated IL-1β release. J Neurochem 2008; 106:271–80.
18. Madry C, Kynagyt A, Arancibia-Cárcamo IL, Jolivet R, Kousaka S, Bryan RM et al. Microglial ramification, surveillance, and interleukin-1β release are regulated by the two-pore domain K+ channel THIK-1. Neuron 2018; 97(2):299–312.e6.
19. Heneka MT, Kummer MP, Stutz A, Delakate A, Secker A, Greip A et al. NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature 2013; 493:674–8.
20. Venera C, Kumar S, Franklin BS, Dierkes T, Brinkshulte R, Tejera D et al. Microglia-derived ASC specks crossed amyloid-β in Alzheimer’s disease. Nature 2017; 552:355–61.
21. Strandgard P, Halsey ML, Albornoz MG, Barrington J, Shaw T, Donnelly R et al. Targeting the IL-33–NLRP3 axis improves therapy for experimental cerebral malaria. Proc Natl Acad Sci USA 2018; 115:7404–9.
22. Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G et al. Identification of a unique TGF-β-dependent molecular and functional signature in microglia. Nature Neurosci 2014; 17:131–41.
23. Humbel C. Organellophagy: microglial brain slice cultures: a review. Neuroscience 2013; 205:86–98.
24. Tseng TC, Schattgen S, Mons K, Wang D, Cerny A, Lutz I et al. A fluorescent reporter mouse for inflammasome assembly demonstrates an important role for cell-bound and free ASC specks during in vivo infection. Cell Rep 2016; 16:571–82.
25. Stoppani L, Buchs P, Muller D. A simple method for organotypic cultures of nervous tissue. J Neurosci Methods 1991; 37:173–82.
26. Zhang Y, Chen K, Sloan SA, Benetti ML, Scholte AB, O’Keefe S et al. An RNA-seq transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci 2014; 34:11929–47.
27. Schau N, Karkanias J, Neff NP, May AP, Quake SR, Wyss-Coray T et al. Single-cell transcriptomics of 20 mouse organs creates a Tabula Muris. Nature 2018; 562:367–72.
28. Sheppard O, Coleman MP, Durrant CS. Lipopolysaccharide-induced neuroinflammation induces pyroptotic disruption through a direct action on brain tissue involving microglia-derived interleukin-1β. J Neuroinflammation 2019; 16:1–13.
29. Streit WJ, Kreutzberg GW. Lectin binding by resting and reactive microglia. J Neurocytol 1987; 16:277–87.
30. Cai X, Chen J, Xu H, Liu S, Qiu-Xing J, Hallmuller R et al. Prion-like polarization underlies signal transduction in antiviral immune defense and inflammasome activation. Cell 2014; 156:1207–22.
31. Franklin BS, Bassullar L, DeNavo D, Ratter JM, Stutz A, Engels G et al. The adaptor ASC has extracellular and “prionoid” activities that propagate inflammation. Nat Immunol 2014; 15:727–37.
32. Coll RC, Robertson AA, Chur JE, Higgins SC, Muñoz-Planillo R, Issera MC et al. A small molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammasome diseases. Nat Med 2015; 21:248–55.
33. Wainamanaker W, Davies R, Namchuk M, Pollard J, Ford P, Kuo G et al. (S)-1-((S)-2-((1-(4-Amino-3-chloro-phenyl)-methanoyl)-amino)-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethyl-3-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an Orally Available Selective Interleukin (IL)-1β Converting Enzyme/ Caspase-1. J Pharmacol Exp Ther 2007; 321:569–16.
34. Baldwin AG, Rivers-Auty J, Daniels MD, White CS, Schwaabe CH, Schulling T et al. Boron-based inhibitors of the NLRP3 inflammasome. J Cell Biol 2017; 214:1321–1335.e5.
35. Timmerman R, Burm SM, Bajramovic JF. An overview of in vitro methods to study microglia. Front Cell Neurosci 2018; 12:242.
36. Grabert K, Michael T, Karavolos MH, Cloherty S, Baillie JK, Stevens MP et al. Microglial brain region-dependent diversity and selective regional sensitivities to aging. Nat Neurosci 2016; 19:504–16.

© 2020 The Authors. Immunology published by John Wiley & Sons Ltd, Immunology, 161, 39–52

NLRP3 inflammasome activation in OHSCs
C. Hoyle et al.

50 Hammond TR, Dufort C, Dissing-Olesen L, Giera S, Young A, Wysoker A et al. Single-cell RNA sequencing of microglia throughout the mouse lifespan and in the injured brain reveals complex cell-state changes. *Immunity* 2019; 50(1):253–71. e8.

51 Ising C, Venegas C, Zhang S, Scheiblich H, Schmidt SV, Vieira-Saecker A et al. NLRP3 inflammasome activation drives tau pathology. *Nature* 2019; 573:669–73.

52 Ravizza T, Lucas SM, Balosso S, Bernardino L, Ku G, Noé F et al. Inactivation of caspase-1 in rodent brain: a novel anticonvulsive strategy. *Epilepsia* 2006; 47:1160–8.

53 Magalhães DM, Pereira N, Rombo DM, Beltrão-Cavacas C, Sebastião AM, Vieira-Saecker A et al. En vivo model of epilepsy in organotypic slices-a new tool for drug screening. *J Neuroinflammation* 2018; 15:203.

54 Bohlen CJ, Bennett PC, Tucker AF, Collins HY, Mulinyawe SB, Barres BA. Diverse requirements for microglial survival, specification, and function revealed by defined-medium cultures. *Neuron* 2017; 94(4):759–73. e8.

55 Moser KV, Schmidt-Kastner R, Hinterhuber H, Hampel C. Brain capillaries and cholinergic neurons persist in organotypic brain slices in the absence of blood flow. *Eur J Neurosci* 2003; 18:85–94.

56 Korvics R, Papagiorgiou I, Heinemann U. Slice cultures as a model to study neurovascular coupling and blood brain barrier in vitro. *Cardiovasc Psychiatry Neurol* 2011; 2011:646958.

57 Avigone E, Lepleux M, Angibaud J, Nagerl UV. Altered morphological dynamics of activated microglia after induction of status epilepticus. *J Neuroinflammation* 2015; 12:202.

58 Haynes SE, Hollopetter G, Yang G, Kupiis D, Daley ME, Gan WB et al. The P2Y12 receptor regulates microglial activation by extracellular nucleotides. *Nat Neurosci* 2006; 9:1512–9.

59 Huuskoisten I, Suusonen T, Miettinen R, van Groen T, Salminen A. A refined in vitro model to study inflammatory responses in organotypic membrane culture of postnatal rat hippocampal slices. *J Neuroinflammation* 2005; 2:21.

60 Masuch A, van der Piil R, Füner L, Wolf Y, Eggen B, Boddeke E et al. Microglia replenished OHSC: a culture system to study in vivo like adult microglia. *Glia* 2016; 64:1285–97.

61 Velasco S, Kedaigle AJ, Simmons SK, Nash A, Rocha M, Quadrato G et al. Individual brain organoids reproducibly form cell diversity of the human cerebral cortex. *Nature* 2019; 570:523–27.

62 Rustenhoven J, Park THH, Schwerdt F, Scooter J, Correia J, Smith AM et al. Isolation of highly enriched primary human microglia for functional studies. *Sci Rep* 2016; 18 (6):19371.

52 © 2020 The Authors. Immunology published by John Wiley & Sons Ltd, *Immunology*, 161, 39–52

**Supporting Information**

Additional Supporting Information may be found in the online version of this article:

**Video S1.** Interleukin-1β production in response to lipopolysaccharide priming.

**Video S2.** Time-lapse imaging of ASC speck formation in ASC–citrine organotypic hippocampal slice cultures.

**Figure S1.** NLRP3 inflammasome priming by Toll-like receptor stimuli in organotypic hippocampal slice cultures.

**Figure S2.** NLRP3 inflammasome priming is consistent in ASC–citrine organotypic hippocampal slice cultures, but they exhibit large aggregates.

**Figure S3.** A range of damage-associated molecular patterns can activate the canonical NLRP3 inflammasome in ASC–citrine organotypic hippocampal slice cultures.

**Figure S4.** Canonical NLRP3 inflammasome activation in microglial cultures.